Patrick J Sinko

List of Publications by Year
in descending order

165	8,708	34105 52	54911 84
papers	citations	h-index	g-index

170	170	170	9278
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sulfur mustard corneal injury is associated with alterations in the epithelial basement membrane and stromal extracellular matrix. Experimental and Molecular Pathology, 2022, 128, 104807.	2.1	2
2	Encapsulation and Controlled Release of a Camptothecin Prodrug from Nanocarriers and Microgels: Tuning Release Rate with Nanocarrier Excipient Composition. Molecular Pharmaceutics, 2021, 18, 1093-1101.	4.6	9
3	Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy. Drug Delivery and Translational Research, 2021, , 1.	5.8	6
4	Systematic Development and Characterization of Novel, High Drug-Loaded, Photostable, Curcumin Solid Lipid Nanoparticle Hydrogel for Wound Healing. Antioxidants, 2021, 10, 725.	5.1	27
5	A Novel Bivalent Mannosylated Targeting Ligand Displayed on Nanoparticles Selectively Targets Anti-Inflammatory M2 Macrophages. Pharmaceutics, 2020, 12, 243.	4.5	17
6	Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy. Journal of Controlled Release, 2020, 323, 71-82.	9.9	16
7	Skin remodeling and wound healing in the Gottingen minipig following exposure to sulfur mustard. Experimental and Molecular Pathology, 2020, 115, 104470.	2.1	5
8	Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 138, 11-22.	4.3	13
9	The effect of size and polymer architecture of doxorubicinâ€“poly(ethylene) glycol conjugate nanocarriers on breast duct retention, potency and toxicity. European Journal of Pharmaceutical Sciences, 2018, 121, 118-125.	4.0	23
10	Evaluation of intraductal delivery of poly(ethylene glycol)â€doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)â€like lesions in rats. Journal of Interdisciplinary Nanomedicine, 2018, 3, 146-159.	3.6	14
11	Biostable Aptamer Rings Conjugated for Targeting Two Biomarkers on Circulating Tumor Cells in Vivo with Great Precision. Chemistry of Materials, 2017, 29, 10312-10325.	6.7	31
12	The nanotechnology race between China and the United States. Nano Today, 2016, 11, 7-12.	11.9	37
13	A Biofunctional Molecular Beacon for Detecting Single Base Mutations in Cancer Cells. Molecular Therapy - Nucleic Acids, 2016, 5, e302.	5.1	11
14	Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model. EBioMedicine, 2016, 4, 104-114.	6.1	59
15	The Architecture and Function of Monoclonal Antibodyâ€Functionalized Mesoporous Silica Nanoparticles Loaded with Mifepristone: Repurposing Abortifacient for Cancer Metastatic Chemoprevention. Small, 2016, 12, 2595-2608.	10.0	41
16	Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugatesâ€”proof of concept for HIV mucosal pre-exposure prophylaxis. Drug Delivery and Translational Research, 2016, 6, 1-16.	5.8	12
17	China and the United Statesâ€”Global partners, competitors and collaborators in nanotechnology development. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 13-19.	3.3	22
18	Singleâ€Step Assembly of Multimodal Imaging Nanocarriers: MRI and Longâ€Wavelength Fluorescence Imaging. Advanced Healthcare Materials, 2015, 4, 1376-1385.	7.6	48

#	Article	IF	Citations
19	Enhanced Specificity in Capturing and Restraining Circulating Tumor Cells with Dual Antibodyâ€“Dendrimer Conjugates. Advanced Functional Materials, 2015, 25, 1304-1313.	14.9	40
20	Responsive foams for nanoparticle delivery. Colloids and Surfaces B: Biointerfaces, 2015, 133, 81-87.	5.0	13
21	Ex vivo and in vivo capture and deactivation of circulating tumor cells by dual-antibody-coated nanomaterials. Journal of Controlled Release, 2015, 209, 159-169.	9.9	33
22	Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Scientific Reports, 2015, 5, 7830.	3.3	25
23	Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial. Journal of Nanobiotechnology, 2015, 13, 9.	9.1	13
24	Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer, 2015, 121, 3036-3045.	4.1	64
25	Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641. Molecular Pharmaceutics, 2015, 12, 1554-1563.	4.6	22
26	Multivalent Conjugation of Antibody to Dendrimers for the Enhanced Capture and Regulation on Colon Cancer Cells. Scientific Reports, 2015, 5, 9445.	3.3	32
27	Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. Journal of Controlled Release, 2015, 219, 669-680.	9.9	39
28	The Architecture and Biological Function of Dual Antibody-Coated Dendrimers: Enhanced Control of Circulating Tumor cells and Their Hetero-Adhesion to Endothelial Cells for Metastasis Prevention. Theranostics, 2014, 4, 1250-1263.	10.0	38
29	Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin. Journal of Applied Microbiology, 2014, 117, 1253-1259.	3.1	53
30	Structural changes in hair follicles and sebaceous glands of hairless mice following exposure to sulfur mustard. Experimental and Molecular Pathology, 2014, 96, 316-327.	2.1	14
31	Gelation Chemistries for the Encapsulation of Nanoparticles in Composite Gel Microparticles for Lung Imaging and Drug Delivery. Biomacromolecules, 2014, 15, 252-261.	5.4	19
32	Pharmaceutical and Toxicological Properties of Engineered Nanomaterials for Drug Delivery. Annual Review of Pharmacology and Toxicology, 2014, 54, 581-598.	9.4	51
33	Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment. Journal of Controlled Release, 2014, 194, 301-309.	9.9	15
34	Therapeutic potential of a non-steroidal bifunctional anti-inflammatory and anti-cholinergic agent against skin injury induced by sulfur mustard. Toxicology and Applied Pharmacology, 2014, 280, 236-244.	2.8	20
35	Polyethylene Glycol-Based Hydrogels for Controlled Release of the Antimicrobial Subtilosin for Prophylaxis of Bacterial Vaginosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 2747-2753.	3.2	24
36	Selective Cytotoxicity and Combined Effects of Camptothecin or Paclitaxel with Sodium-R-Alpha Lipoate on A549 Human Non-Small Cell Lung Cancer Cells. Nutrition and Cancer, 2014, 66, 492-499.	2.0	17

#	Article	IF	Citations
37	Optimal structural design of mannosylated nanocarriers for macrophage targeting. Journal of Controlled Release, 2014, 194, 341-349.	9.9	40
38	Toxicodynamics of rigid polystyrene microparticles on pulmonary gas exchange in mice: Implications for microemboli-based drug delivery systems. Toxicology and Applied Pharmacology, 2013, 266, 214-223.	2.8	4
39	Novel Monodisperse PEGtide Dendrons: Design, Fabrication, and Evaluation of Mannose Receptor-Mediated Macrophage Targeting. Bioconjugate Chemistry, 2013, 24, 1332-1344.	3.6	29
40	Optimization of cell receptor-specific targeting through multivalent surface decoration of polymeric nanocarriers. Journal of Controlled Release, 2013, 168, 41-49.	9.9	67
41	The generation of 4-hydroxynonenal, an electrophilic lipid peroxidation end product, in rabbit cornea organ cultures treated with UVB light and nitrogen mustard. Toxicology and Applied Pharmacology, 2013, 272, 345-355.	2.8	31
42	Safety, Formulation and In Vitro Antiviral Activity of the Antimicrobial Peptide Subtilosin Against Herpes Simplex Virus Type 1. Probiotics and Antimicrobial Proteins, 2013, 5, 26-35.	3.9	88
43	Core Functional Sequence of C-terminal GAG-binding Domain Directs Cellular Uptake of IGFBP-3-derived Peptides. Protein and Peptide Letters, 2013, 21, 124-131.	0.9	3
44	Susceptibility ofGardnerella vaginalisBiofilms to Natural Antimicrobials Subtilosin,Îµ-Poly-L-Lysine, and Lauramide Arginine Ethyl Ester. Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-9.	1.5	44
45	Influence of Molecular Size on the Retention of Polymeric Nanocarrier Diagnostic Agents in Breast Ducts. Pharmaceutical Research, 2012, 29, 2377-2388.	3.5	34
46	Microfluidic Generation of Droplets with a High Loading of Nanoparticles. Langmuir, 2012, 28, 13143-13148.	3.5	16
47	The Natural Antimicrobial Peptide Subtilosin Acts Synergistically with Glycerol Monolaurate, Lauric Arginate, and Îµ-Poly- <scp>l</scp> -Lysine against Bacterial Vaginosis-Associated Pathogens but Not Human Lactobacilli. Antimicrobial Agents and Chemotherapy, 2012, 56, 1756-1761.	3.2	44
48	Biodistribution and renal clearance of biocompatible lung targeted poly(ethylene glycol) (PEG) nanogel aggregates. Journal of Controlled Release, 2012, 164, 65-73.	9.9	42
49	Attenuation of acute nitrogen mustard-induced lung injury, inflammation and fibrogenesis by a nitric oxide synthase inhibitor. Toxicology and Applied Pharmacology, 2012, 265, 279-291.	2.8	50
50	Noninvasive Detection of Passively Targeted Poly(ethylene glycol) Nanocarriers in Tumors. Molecular Pharmaceutics, 2012, 9, 144-155.	4.6	22
51	The role of crystallinity on differential attachment/proliferation of osteoblasts and fibroblasts on poly (caprolactone-co-glycolide) polymeric surfaces. Frontiers of Materials Science, 2012, 6, 47-59.	2.2	55
52	Selective cytotoxicity and combinatorial effects of camptothecin or paclitaxel with sodiumâ€Râ€alpha lipoic acid on A549 human nonâ€small cell lung cancer cells. FASEB Journal, 2012, 26, 1038.14.	0.5	0
53	Sulfur mustard-induced pulmonary injury: Therapeutic approaches to mitigating toxicity. Pulmonary Pharmacology and Therapeutics, 2011, 24, 92-99.	2.6	102
54	Regulation of Hsp27 and Hsp70 expression in human and mouse skin construct models by caveolae following exposure to the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide. Toxicology and Applied Pharmacology, 2011, 253, 112-120.	2.8	27

#	Article	IF	Citations
55	Structural changes in the skin of hairless mice following exposure to sulfur mustard correlate with inflammation and DNA damage. Experimental and Molecular Pathology, 2011, 91, 515-527.	2.1	55
56	Elucidation of the Molecular Mechanisms of Action of the Natural Antimicrobial Peptide Subtilosin Against the Bacterial Vaginosis-associated Pathogen Gardnerella vaginalis. Probiotics and Antimicrobial Proteins, 2011, 3, 41-47.	3.9	53
57	Doxycycline hydrogels with reversible disulfide crosslinks for dermal wound healing of mustard injuries. Biomaterials, 2011, 32, 1204-1217.	11.4	120
58	Two Sorting Motifs, a Ubiquitination Motif and a Tyrosine Motif, Are Involved in HIV-1 and Simian Immunodeficiency Virus Nef-Mediated Receptor Endocytosis. Journal of Immunology, 2011, 186, 5807-5814.	0.8	9
59	Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Advanced Drug Delivery Reviews, 2010, 62, 518-531.	13.7	134
60	Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. Journal of Controlled Release, 2010, 143, 31-37.	9.9	94
61	Role of MAP kinases in regulating expression of antioxidants and inflammatory mediators in mouse keratinocytes following exposure to the half mustard, 2-chloroethyl ethyl sulfide. Toxicology and Applied Pharmacology, 2010, 245, 352-360.	2.8	51
62	Expression of proliferative and inflammatory markers in a full-thickness human skin equivalent following exposure to the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide. Toxicology and Applied Pharmacology, 2010, 249, 178-187.	2.8	32
63	Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. International Journal of Pharmaceutics, 2010, 402, 64-71.	5.2	41
64	Doxycycline loaded poly(ethylene glycol) hydrogels for healing vesicant-induced ocular wounds. Biomaterials, 2010, 31, 964-974.	11.4	71
65	Biodegradable poly(ethylene glycol) hydrogels based on a self-elimination degradation mechanism. Biomaterials, 2010, 31, 6675-6684.	11.4	62
66	Oxidants and antioxidants in sulfur mustardâ€“induced injury. Annals of the New York Academy of Sciences, 2010, 1203, 92-100.	3.8	124
67	Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anti-Cancer Drugs, 2010, 21, 65-76.	1.4	65
68	Mechanisms Mediating the Vesicant Actions of Sulfur Mustard after Cutaneous Exposure. Toxicological Sciences, 2010, 114, 5-19.	3.1	179
69	A Series of Î±-Amino Acid Ester Prodrugs of Camptothecin: In Vitro Hydrolysis and A549 Human Lung Carcinoma Cell Cytotoxicity. Journal of Medicinal Chemistry, 2010, 53, 1038-1047.	6.4	48
70	Doxycycline Hydrogels as a Potential Therapy for Ocular Vesicant Injury. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 407-419.	1.4	58
71	Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy. Journal of Drug Delivery Science and Technology, 2009, 19, 3-14.	3.0	25
72	Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. Journal of Controlled Release, 2009, 137, 152-159.	9.9	72

#	Article	IF	Citations
73	Nonenzymatic, Selfâ€Elimination Degradation Mechanism of Glutathione. Chemistry and Biodiversity, 2009, 6, 527-539.	2.1	21
74	Multimeric peptide-based PEG nanocarriers with programmable elimination properties. Biomaterials, 2009, 30, 5649-5659.	11.4	6
75	Endocytosis and Membrane Potential Are Required for HeLa Cell Uptake of R.I.-CKTat9, a Retro-Inverso Tat Cell Penetrating Peptide. Molecular Pharmaceutics, 2009, 6, 836-848.	4.6	56
76	Optimizing Size and Copy Number For PEG-fMLF (N-Formyl-methionyl-leucyl-phenylalanine) Nanocarrier Uptake by Macrophages. Bioconjugate Chemistry, 2008, 19, 28-38.	3.6	31
77	Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats. Drug Metabolism and Disposition, 2008, 36, 863-869.	3.3	31
78	Synthesis, Characterization, and In Vitro Assay of Folic Acid Conjugates of 3â€²-Azido-3â€²-Deoxythymidine (AZT): Toward Targeted AZT Based Anticancer Therapeutics. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 173-185.	1.1	15
79	Recent Trends in Targeted Anticancer Prodrug and Conjugate Design. Current Medicinal Chemistry, 2008, 15, 1802-1826.	2.4	208
80	Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: A promising new approach to the treatment of multidrug resistant cancer. Cancer Letters, 2007, 253, 115-123.	7.2	10
81	Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. Journal of Pharmacy and Pharmaceutical Sciences, 2007, 10, 519.	2.1	31
82	Peritoneal Macrophage Uptake, Pharmacokinetics and Biodistribution of Macrophage-Targeted PEG-fMLF (N-Formyl-Methionyl-Leucyl-Phenylalanine) Nanocarriers for Improving HIV Drug Delivery. Pharmaceutical Research, 2007, 24, 2110-2119.	3.5	39
83	Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Research and Therapy, 2006, 3, 12.	1.7	20
84	Drug delivery across the bloodâ€“brain barrier: why is it difficult? how to measure and improve it?. Expert Opinion on Drug Delivery, 2006, 3, 419-435.	5.0	54
85	siRNAâ€”Getting the message out. European Journal of Pharmaceutical Sciences, 2006, 27, 401-410.	4.0	34
86	Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: Evidence for multifactorial multidrug resistance. European Journal of Pharmaceutical Sciences, 2006, 29, 102-110.	4.0	30
87	Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Release, 2006, 112, 333-342.	9.9	69
88	Tumor-targeted and activated bioconjugates for improved camptothecin delivery. Anti-Cancer Drugs, 2005, 16, 763-775.	1.4	28
89	Effect of experimental pH on the in vitro permeability in intact rabbit intestines and Caco-2 monolayer. European Journal of Pharmaceutical Sciences, 2005, 25, 193-200.	4.0	34
90	Delineation of Human Peptide Transporter 1 (hPepT1)-Mediated Uptake and Transport of Substrates with Varying Transporter Affinities Utilizing Stably Transfected hPepT1/Madin-Darby Canine Kidney Clones and Caco-2 Cells. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1093-1100.	2.5	38

#	Article	IF	Citations
91	The Role of N-Linked Glycosylation in Protein Folding, Membrane Targeting, and Substrate Binding of Human Organic Anion Transporter hOAT4. Molecular Pharmacology, 2005, 67, 868-876.	2.3	103
92	P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1249-1256.	2.5	76
93	THE BLOOD-BRAIN BARRIER SODIUM-DEPENDENT MULTIVITAMIN TRANSPORTER: A MOLECULAR FUNCTIONAL IN VITRO-IN SITU CORRELATION. Drug Metabolism and Disposition, 2005, 33, 1547-1554.	3.3	29
94	Estimating Human Drug Oral Absorption Kinetics from Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for ka and Fa. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 391-399.	2.5	58
95	Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12962-12967.	7.1	319
96	Intestinal Drug Transporters: In Vivo Function and Clinical Importance. Current Drug Metabolism, 2004, 5, 109-124.	1.2	131
97	DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS. Drug Metabolism and Disposition, 2004, 32, 1293-1298.	3.3	21
98	Differentiation of Gut and Hepatic First Pass Metabolism and Secretion of Saquinavir in Ported Rabbits. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 359-366.	2.5	28
99	Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. Journal of Controlled Release, 2004, 100, 275-292.	9.9	64
100	Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Medicine, 2004, 2, 16.	5.5	48
101	Practical Aspects of Transporter Model Systems: A Case Study Involving SQV. Drug Metabolism Reviews, 2004, 36, 377-389.	3.6	6
102	Human Organic Anion-Transporting Polypeptide OATP-A (SLC21A3) Acts in Concert with P-Glycoprotein and Multidrug Resistance Protein 2 in the Vectorial Transport of Saquinavir in Hep G2 Cells. Molecular Pharmaceutics, 2004, 1, 49-56.	4.6	97
103	Quantitative Assessment of the Cell Penetrating Properties of RI-Tat-9:â€‰ Evidence for a Cell Type-Specific Barrier at the Plasma Membrane of Epithelial Cells. Molecular Pharmaceutics, 2004, 1, 145-155.	4.6	29
104	Synthesis of Poly(ethylene glycol)-Based Saquinavir Prodrug Conjugates and Assessment of Release and Anti-HIV-1 Bioactivity Using a Novel Protease Inhibition Assay. Bioconjugate Chemistry, 2004, 15, 1322-1333.	3.6	44
105	Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharmaceutical Research, 2003, 20, 1015-1021.	3.5	102
106	Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers. Pharmaceutical Research, 2003, 20, 390-396.	3.5	13
107	Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. Journal of Controlled Release, 2003, 91, 61-73.	9.9	172
108	The Effect of Cell Culture Conditions on Saquinavir Transport Through, and Interactions with, MDCKII Cells Overexpressing hMDR1. Journal of Pharmaceutical Sciences, 2003, 92, 1957-1967.	3.3	28

#	Article	IF	Citations
109	A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials, 2003, 24, 11-18.	11.4	121
110	Multiple-Peptide Conjugates for Binding Î²-Amyloid Plaques of Alzheimer's Disease. Bioconjugate Chemistry, 2003, 14, 86-92.	3.6	60
111	Involvement of multidrug resistance-associated proteins in regulating cellular levels of (â¯)-epigallocatechin-3-gallate and its methyl metabolites. Biochemical and Biophysical Research Communications, 2003, 310, 222-227.	2.1	174
112	In Silico Tools for Drug Absorption Prediction. American Journal of Drug Delivery, 2003, 1, 133-148.	0.6	4
113	Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1. Drug Metabolism and Disposition, 2002, 30, 763-770.	3.3	113
114	Delineating the Contribution of Secretory Transporters in the Efflux of Etoposide Using Madin-Darby Canine Kidney (MDCK) Cells Overexpressing P-Glycoprotein (Pgp), Multidrug Resistance-Associated Protein (MRP1), and Canalicular Multispecific Organic Anion Transporter (cMOAT). Drug Metabolism and Disposition, 2002, 30, 457-463.	3.3	84
115	Direct Evidence that Saquinavir Is Transported by Multidrug Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2). Antimicrobial Agents and Chemotherapy, 2002, 46, 3456-3462.	3.2	127
116	Conjugates Bearing Multiple Formyl-Methionyl Peptides Display Enhanced Binding to but Not Activation of Phagocytic Cells. Bioconjugate Chemistry, 2002, 13, 216-223.	3.6	15
117	Physiologically-based pharmacokinetic simulation modelling. Advanced Drug Delivery Reviews, 2002, 54, 433-451.	13.7	152
118	Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemotherapy and Pharmacology, 2002, 50, 143-150.	2.3	116
119	Pharmacokinetic Studies in Tg.AC and FVB Mice Administered [14C]Benzene either by Oral Gavage or Intradermal Injection. Toxicology and Applied Pharmacology, 2001, 174, 139-145.	2.8	10
120	Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide. Pharmaceutical Research, 2001, 18, 950-956.	3.5	59
121	Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. Pharmaceutical Research, 2001, 18, 1721-1728.	3.5	15
122	Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide. Journal of Controlled Release, 2001, 77, 199-212.	9.9	43
123	Effect of diverse datasets on the predictive capability of ADME models in drug discovery. Drug Discovery Today, 2001, 6, 54-61.	6.4	23
124	Pharmacokinetics of Benzene Following an Oral or Intradermal Dose in FVB and Tg.AC Mice. Advances in Experimental Medicine and Biology, 2001, 500, 455-458.	1.6	1
125	Active efflux kinetics of etoposide from rabbit small intestine and colon. Biopharmaceutics and Drug Disposition, 2000, 21, 83-93.	1.9	11
126	Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharmaceutics and Drug Disposition, 2000, 21, 165-174.	1.9	31

#	Article	IF	Citations
127	Oral delivery of salmon calcitonin. Advanced Drug Delivery Reviews, 2000, 42, 225-238.	13.7	104
128	Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. Journal of Controlled Release, 2000, 69, 53-67.	9.9	14
129	Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. Journal of Controlled Release, 2000, 69, 69-80.	9.9	25
130	Development of predictive pharmacokinetic simulation models for drug discovery. Journal of Controlled Release, 2000, 65, 55-62.	9.9	109
131	Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin absorption in dogs. Pharmaceutical Research, 2000, 17, 284-290.	3.5	20
132	An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems. Vaccine, 2000, 18, 2600-2612.	3.8	39
133	Regional oral absorption, hepatic first-pass effect, and non-linear disposition of salmon calcitonin in beagle dogs. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50, 205-211.	4.3	24
134	Impact of regional intestinal pH modulation on absorption of peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs. Pharmaceutical Research, 1999, 16, 1233-1239.	3.5	35
135	Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharmaceutical Research, 1999, 16, 527-533.	3.5	63
136	Determining the absolute surface hydrophobicity of microparticulates using thin layer wicking. Journal of Controlled Release, 1999, 59, 173-185.	9.9	32
137	Preface. Advanced Drug Delivery Reviews, 1999, 39, 1-3.	13.7	0
138	Involvement of multiple transporters in the oral absorption of nucleoside analogues. Advanced Drug Delivery Reviews, 1999, 39, 183-209.	13.7	63
139	Oral absorption of the HIV protease inhibitors: a current update. Advanced Drug Delivery Reviews, 1999, 39, 211-238.	13.7	129
140	Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharmaceutical Research, 1998, 15, 1160-1167.	3.5	200
141	The effect of physical barriers and properties on the oral absorption of particulates. Advanced Drug Delivery Reviews, 1998, 34, 135-154.	13.7	230
142	Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir. 1. Interactions with peptides, organic anions and organic cations in rats. , 1998, 19, 209-217.		79
143	Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir. Biochemical and Biophysical Research Communications, 1998, 250, 246-251.	2.1	207
144	Influence of the Microporous Substratum and Hydrodynamics on Resistances to Drug Transport in Cell Culture Systems: Calculation of Intrinsic Transport Parameters. Journal of Pharmaceutical Sciences, 1997, 86, 1448-1457.	3.3	28

#	Article	IF	Citations
145	Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages. Pharmaceutical Research, 1997, 14, 757-762.	3.5	99
146	Oral absorption of anti- AIDS nucleoside analogues. 3. Regional absorption andin vivo permeability of 2â€², 3â€² - dideoxyinosine in an intestinal-vascular access port (IVAP) dog model. , 1997, 18, 697-710.		16
147	Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. Journal of Applied Polymer Science, 1997, 63, 1481-1492.	2.6	166
148	Determination intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans. Pharmaceutical Research, 1996, 13, 108-113.	3.5	14
149	Analysis of intestinal perfusion data for highly permeable drugs using a numerical aqueous resistance--nonlinear regression method. Pharmaceutical Research, 1996, 13, 570-576.	3.5	5
150	Oral Absorption of Anti-Acquired Immune Deficiency Syndrome Nucleoside Analogues. 2. Carrier-Mediated Intestinal Transport of Stavudine in Rat and Rabbit Preparationsâ€. Journal of Pharmaceutical Sciences, 1996, 85, 478-485.	3.3	14
151	Oral absorption of anti-aids nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations. Journal of Pharmaceutical Sciences, 1995, 84, 959-965.	3.3	41
152	Utility of Pharmacodynamic Measures for Assessing the Oral Bioavailability of Peptides. 1. Administration of Recombinant Salmon Calcitonin in Rats. Journal of Pharmaceutical Sciences, 1995, 84, 1374-1378.	3.3	40
153	Site-specific oral absorption of didanosine: in situ characterization and correlation with extent of absorption in vivo. International Journal of Pharmaceutics, 1994, 109, 125-133.	5.2	16
154	Characterization of the Oral Absorption of Some Î²-Lactams Effect of the Î±-Amino Side Chain Group. Journal of Pharmaceutical Sciences, 1993, 82, 897-900.	3.3	17
155	Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: theoretical development and applications. Pharmaceutical Research, 1993, 10, 271-275.	3.5	26
156	Intestinal absorption of peptides and peptide analogues: implications of fasting pancreatic serine protease levels and pH on the extent of oral absorption in dogs and humans. Pharmaceutical Research, 1992, 09, 320-325.	3.5	7
157	Characterization of the oral absorption of several aminopenicillins: Determination of intrinsic membrane absorption parameters in the rat intestine in situ. International Journal of Pharmaceutics, 1992, 85, 181-187.	5.2	19
158	Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharmaceutical Research, 1991, 08, 979-988.	3.5	154
159	Predicting Oral Drug Absorption in Humans: A Macroscopic Mass Balance Approach for Passive and Carrier-Mediated Compounds. , 1991, , 3-11.		3
160	Characterization of the Oral Absorption of Î²-Lactam Antibiotics II: Competitive Absorption and Peptide Carrier Specificity. Journal of Pharmaceutical Sciences, 1989, 78, 723-727.	3.3	50
161	Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharmaceutical Research, 1988, 05, 651-654.	3.5	268
162	Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharmaceutical Research, 1988, 05, 645-650.	3.5	80

#	Article	IF	Citations
163	Membrane permeability parameters for some amino acids and Î²-lactam antibiotics: Application of the boundary layer approach. Journal of Theoretical Biology, 1988, 131, 107-114.	1.7	52
164	Carrier mediated transport of amino acids, small peptides, and their drug analogs. Journal of Controlled Release, 1987, 6, 115-121.	9.9	18
165	Drug Transporters in the Intestine. , 0, , 495-515.		1